MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: efimosfermin alfa

efimosfermin alfa

Latest news

Tag

Gastroenterology

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial

The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.

Feb 16, 2026
Clinical Updates

Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 2a Results

Efimosfermin alfa, a long-acting FGF21 analogue, demonstrated a favorable safety profile and significant reductions in hepatic fat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase 2a randomized controlled

Aug 2, 2025

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story